Lung infections are a significant cause of reduced quality of life and early death in persons living the CF. Infections start early in life and are typically treated with multiple lifetime courses of antibiotics. Increased antibiotic exposures lead to drug resistance and need to use of drugs with increasing side effects. Colistin is a drug that has been used clinically for bacteria with resistance to multiple drugs. Use of colisitin has not been well studied in patients with CF with a unique drug metabolism profile. This study will aim to define a dosing strategy specific to patients with CF.
|Effective start/end date||11/1/17 → 10/31/20|
- Cystic Fibrosis Foundation Therapeutics, Inc. (PRICKE17A0-I)